

**Publication of materials for holding a Extraordinary General Meeting of Shareholders of  
“Sopharma” AD, scheduled for 4 August 2023**

**Sofia, Bulgaria**, 4 July 2023 - According to the requirements of Art. 100t of the Law on Public Offering of Securities the Board of directors of “**Sopharma**” AD (SFA: “BSE – Sofia”, SPH: Warsaw Stock Exchange) presents the following materials on the agenda of AGM convened for 4 August 2023 to the attention of shareholders, which will be available on the website of Extri News ([www.x3news.com](http://www.x3news.com)), in the FSC system, on the Company's website <https://www.sopharmagroup.com/bg/investitori/obshcho-sbranie-na-akcionerite> and on the website [www.investor.bg](http://www.investor.bg), as well as in hard copy at the address of the Company:

1. Minutes of a meeting of the Board of Directors for convening an Extraordinary Meeting of Shareholders of “Sopharma” AD;
2. Invitation to convene the Extraordinary Meeting of Shareholders (AGM) of “Sopharma” AD;
3. Power of attorney – an example for representing a shareholder at the AGM;
4. Declaration for voting by correspondence – an example for the AGM;
5. **For item 2 of the agenda:** Contract for transformation through merger of Biopharm Engineering AD into Sopharma AD concluded on 23.01.2023, Annex No 1 of 21.03.2023 and Annex No 2 of 15.05.2023 thereto;
6. **For item 3 of the agenda:** Report of the Board of Directors of Sopharma AD to the shareholders of the Company on the transformation through merger of Biopharm Engineering AD into Sopharma AD;
7. **For items 4 of the agenda;** Report of the examiner under art. 262m of the Commercial Law on the transformation through merger of Biopharm Engineering AD into Sopharma AD;
8. **For item 5 of the agenda:** Statute of the audit committee.

Please, pursuant to Art. 100k, para. 1 of LPOS, to give publicity to the above information.



Pelagia Viatcheva

Investor Relations Director



#### **Information about the company**

##### **Sopharma AD**

*Nearly 90 years of tradition and modernity - contemporary production, European standards and quality, best practices in the field of corporate and social responsibility.*

*Sopharma AD is the most successful Bulgarian company after the privatization, as from 2000 to today, the company realized 10 times growth in market capitalization and 25 times revenue growth. Over the past 10 years, Sopharma AD has been a leader in the pharmaceutical sector in Bulgaria.*

*Sopharma AD produces active substances and medicinal products; conducts activities related to development and implementation in the field of phytochemistry, chemistry and pharmacy, provides services related to production and other.*

*With 9 pharmaceutical plants in the country and the only ampoule factory in Bulgaria the company produces 3 billion tablets, 20 million syrup forms, has an authorization for over 200 generic products, 15 traditional products, 12 of which are plant-based, and uses more than 1500 tons of medicinal plants in its products.*

*Sopharma AD has an active and key role in raising the standard of living, in making people healthier, happier and protected. Sopharma AD is constantly investing in new technologies, innovations and research. The company maintains a dialogue with all players in the pharmaceutical industry and strives to contribute to improving the healthcare sector.*

##### **Sopharma Group**

*Sopharma Group is a vertically integrated healthcare business that operates in important health related sectors such as pharmaceuticals, hospital supplies, pharmaceutical products distribution and many others. "Sopharma" AD and its production subsidiaries have 8 pharmaceutical plants in Bulgaria, complying with the requirements of EU- GMP.*